Amprion’s biomarker testing technology helps biopharma partners identify new drug candidates and underlying pathologies to pursue failed endpoints.
For the first time in history, we can track the misfolded proteins associated with brain diseases in the early stages.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.